Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
Open Access
- 29 June 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 10 (1), 337
- https://doi.org/10.1186/1471-2407-10-337
Abstract
We conducted a systematic review and meta-analysis to clarify the risk of early and late cardiotoxicity of anthracycline agents in patients treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma.This publication has 94 references indexed in Scilit:
- EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentaryEuropean Journal of Cancer, 2009
- Cause-Specific Late Mortality Among 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor StudyJNCI Journal of the National Cancer Institute, 2008
- American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late EffectsJournal of Clinical Oncology, 2007
- Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic reviewBritish Journal of Cancer, 2007
- Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5Journal of Clinical Oncology, 2005
- DexrazoxaneDrugs, 2005
- Cardiovascular Complications of Cancer TherapyCirculation, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 2000
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986